QLT (QLTI) Announces Results from Phase II RADICAL in Patients with Wet AMD; Fewer Retreatments Needed
Tweet Send to a Friend
QLT Inc. (Nasdaq: QLTI) today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
